• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Upstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 7:05:10 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPB alert in real time by email
    8-K
    false000202262600020226262025-05-062025-05-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of report (date of earliest event reported): May 06, 2025

     

     

    UPSTREAM BIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

    001-42366

    38-4187694

    (State or other jurisdiction
    of incorporation)

    (Commission file number)

    (IRS employer
    identification no.)

     

     

     

     

     

    890 Winter Street

    Suite 200

     

    Waltham, Massachusetts

     

    02451

    (Address of principal executive offices)

     

    (Zip code)

     

    Registrant’s telephone number, including area code: (781) 208-2466

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    UPB

     

    The Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, Upstream Bio, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information included under Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits

     

     

     

    99.1

     

    Press Release issued by Upstream Bio, Inc. on May 6, 2025, furnished herewith.

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Upstream Bio, Inc.

     

     

     

     

    Date:

    May 6, 2025

    By:

    /s/ E. Rand Sutherland

     

     

     

    E. Rand Sutherland, M.D.
    Chief Executive Officer

     


    Get the next $UPB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPB

    DatePrice TargetRatingAnalyst
    11/5/2024$75.00Overweight
    Piper Sandler
    11/5/2024$38.00Overweight
    JP Morgan
    11/5/2024Outperform
    William Blair
    11/5/2024Buy
    TD Cowen
    More analyst ratings

    $UPB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chimovits Erez bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:19:30 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $14,025,000 worth of shares (825,000 units at $17.00) and converted options into 3,609,789 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:17:52 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ai Upstream Llc bought $19,975,000 worth of shares (1,175,000 units at $17.00) and converted options into 4,319,410 shares (SEC Form 4)

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    10/17/24 4:05:04 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    SEC Filings

    View All

    Upstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Upstream Bio, Inc. (0002022626) (Filer)

    9/2/25 8:38:15 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Upstream Bio Inc.

    SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)

    8/6/25 12:19:41 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Upstream Bio Inc.

    10-Q - Upstream Bio, Inc. (0002022626) (Filer)

    8/6/25 7:12:53 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Renaud Ronald C Jr

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    6/12/25 4:17:33 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ruddy Marcella K.

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    6/12/25 4:17:30 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chimovits Erez

    4 - Upstream Bio, Inc. (0002022626) (Issuer)

    6/12/25 4:17:31 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Upstream Bio with a new price target

    Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00

    11/5/24 6:29:20 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan initiated coverage on Upstream Bio with a new price target

    JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00

    11/5/24 6:28:28 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Upstream Bio

    William Blair initiated coverage of Upstream Bio with a rating of Outperform

    11/5/24 6:28:02 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

    WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025 at 10:30 a.m. ET. A live webcast of the fireside chat will be available under the Events tab on the Investors section of the Company's website. A replay will be posted on the Company's website following the presentation. About Upstream BioUpstream Bio is a clinical-stage biotechno

    9/9/25 7:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    – In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

    9/2/25 6:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl

    9/1/25 5:00:00 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Leadership Updates

    Live Leadership Updates

    View All

    Upstream Bio Appoints Stacy Price as Chief Technology Officer

    WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr

    5/20/25 7:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio Appoints Allison Ambrose as General Counsel

    WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to

    12/17/24 8:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    11/7/24 9:24:55 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Upstream Bio Inc.

    SC 13D - Upstream Bio, Inc. (0002022626) (Subject)

    10/22/24 4:06:27 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Upstream Bio Inc.

    SC 13G - Upstream Bio, Inc. (0002022626) (Subject)

    10/18/24 6:10:56 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPB
    Financials

    Live finance-specific insights

    View All

    Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    – In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in placebo-adjusted endoscopic nasal polyp score (NPS) of -1.8 (p<0.0001) – – Significant and clinically meaningful improvements were observed in key secondary endpoints, including -0.8 (p=0.0003) reduction in nasal congestion score and 76% (p=0.03) reduction in need for surgery or systemic corticosteroids – – No serious adverse events (SAEs) observed; generally well tolerated safety profile consistent with previous studies – – Observed clinical effect on endoscopic NPS in this Phase 2 trial suggests verekit

    9/2/25 6:00:00 AM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

    WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line data from the Phase 2 VIBRANT trial of verekitug, the only known clinical-stage monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), on Tuesday, September 2, 2025. The VIBRANT trial (NCT06164704) was a Phase 2 global, randomized, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in adults with CRSwNP. Participants received either 100 mg of verekitug or pl

    9/1/25 5:00:00 PM ET
    $UPB
    Biotechnology: Pharmaceutical Preparations
    Health Care